Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors
Toshio Shimizu(Wakayama Medical University), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), K. Papadopoulos(South Texas Accelerated Research Therapeutics), Patricia LoRusso(Yale Cancer Center), Amita Patnaik(South Texas Accelerated Research Therapeutics), Drew Rasco(Texas Oncology), Maurizio Voi(Curis (United States)), Glenda Chambers(South Texas Accelerated Research Therapeutics), Jing Wang(Yuhuangding Hospital), Lon Smith(Texas Oncology), Theresa A. Mays(Texas Oncology), Muralidhar Beeram(Urology San Antonio), Robert J Laliberte(Inserm), Anna Ma(Metis Design Corporation (United States))
Cited by 82
Related Papers
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
E-CELL: software environment for whole-cell simulation.
|Bioinformatics|1999|765
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
|Clinical Cancer Research|2012|432